Full-Time

Country Clinical Operations Head

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

No salary listed

Maidenhead, UK

Hybrid

Mandatory hybrid model based in Maidenhead office Tuesday-Thursday

Category
Biology & Biotech (1)
Required Skills
Google Cloud Platform

Get referred to AbbVie

Find people who can refer or advise you

Requirements
  • Education: Bachelors or equivalent degree, health related (e.g. Medical, Scientific, Nursing, Pharmacy) preferred.
  • Strong experience in clinical research, demonstrating a high level of expertise on study monitoring and management across multiple Therapeutic Areas, Study Phases and in fully cycle (startup to closeout) processes. Solid understanding of drug development process (and medical device preferred) and requirements such as GCP, ICH, etc. Robust knowledge of local clinical trial setting (regulatory and healthcare environment).
  • Experience in line management of staff including acquisition of talent, performance management, growth and development, managing employee relations, coaching and mentoring of staff and teams preferred.
  • Proven track record in project management, strong planning and organizational skills and a high level of adaptability in a dynamic environment with experience leading (within country or region) projects with competing deadlines.
  • Experience in setting and driving the strategy and leading the management and completion of global trials assigned to the country/ies. Experience in functional budget planning (preferred), resource planning & assignment, quality management at country or regional level.
  • Strong leadership competencies. Robust experience in leading teams through change, leveraging team contribution to support business strategies. Gives guidance and inspiration to their direct reports and teammates.
  • Fosters an environment that promotes the sharing of ideas, information, and best practices (internal and external to the organization) to drive continuous improvement.
  • Proven leadership skills in a cross-functional, matrix environment, with ability to influence and align key stakeholders, forge strong partnership where needed and promote seamless collaboration at all levels. Proactively responds to the needs of others and makes their own needs and business strategy known. Externally approaches stakeholders with customer service orientation in order to be perceived as a clinical study partner of choice.
  • Strong analytical and critical thinking skills to evaluate complex issues from multiple perspectives and drive smart decision making.
  • Excellent interpersonal skills with the ability to communicate persuasively in a succinct and comprehensive manner to colleagues at all levels. Engenders trust throughout the organization and seeks to grow and stretch key talent for future possibilities. Acts with integrity in accordance with AbbVie code of business conduct and leadership values.
  • Mandatory hybrid model based in Maidenhead officeTuesday-Thursday
Responsibilities
  • Defines the country strategy and operational plans aligned with AbbVie's business priorities, Clinical Development Operations and affiliate objectives in order to position the country for near and long term success.
  • Continuously assess country site footprint across all therapeutic areas, expanding where there are opportunities and needs to support the pipeline.
  • Provides leadership, strategic direction and oversight for all country activities across all stages of the clinical trial (country & site feasibility, selection and start-up, throughout study conduct and closure), ensuring high quality and scientific integrity of trial deliverables. Accountable for all Country level CDO deliverables for internally managed Clinical Studies.
  • Provide leadership and oversight to the clinical research team including, but not limited to: performing accompanied visits (on-site and off-site) accelerate AbbVie's priority programs through close collaboration with internal and external stakeholders conduct trend analysis and gap assessments to proactively identify training and developmental opportunities for assigned personnel drive performance and address gaps to ensure the team achieves country and site level KPIs, KRIs & metrics
  • Partners with internal stakeholders to drive insightful and impactful interactions and promote the value of the clinical research team through the contribution to the R&D portfolio success. Partners with GMA Medical Affairs Head to co-Lead the 'One R&D' collaboration within the affiliate. Operates as 'CDO Head' to support and represent non-CSM CDO personnel based within the affiliate.
  • Accountable for the identification of resource needs, management of the allocated resources and timely hiring of clinical research staff to support clinical trials execution. Responsible for maintaining team capacity aligned with organizational needs, applying flexible and effective approaches for responsibilities assignment, that promotes staff development and retention.
  • Defines and implements the optimal team organizational structure to support the needs of the business which allows the team to operate in a matrix and evolving environment, ensuring effective collaboration with key capabilities and roles. Identifies and implements strategies and tactics to ensure continuous efficiency, effectiveness and productivity of the country. Responsible for building a high performing team, accountable for the operational excellence in the execution of clinical trials.
  • Accountable for ensuring adherence to applicable global and local regulations, ICH Guidelines and AbbVie Quality Management System, promoting a quality driven local organization, oriented to continuous improvement and excellence. Accountable for country Intelligence and impact analysis of all significant changes affecting the conduct of clinical studies, and for implementing procedural adjustments and orientation to guarantee team preparedness, alignment and compliance, as needed.
  • Ensures Inspection Readiness across all activities, through effective leadership and oversight, promoting quality-driven initiatives. Responsible for the development of a critical thinking organization, focused on gap assessment, risk identification and mitigation strategies. Acts as the country expert for audit and inspection related processes, and may also serve as the local AbbVie host for in-country inspections/audits.
  • Accountable for functional budget planning and management, ensuring accurate budgets and forecasts. Works closely with finance counterparts, guaranteeing seamless budget control processes and accurate communication of budget status, cost and issues to allow timely decision-making. Responsible for country feasibility, site selection strategy, and expanding AbbVie's site footprint within the country to support the pipeline.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Skyrizi and Rinvoq projected to exceed $27 billion in combined sales by 2027
  • FDA approval for pediatric Skyrizi treats 20,000 US children under ten with psoriasis annually
  • Phase 3 EPCORE FL-1 trial showed TEPKINLY reduced lymphoma progression or death risk by 79%

What critics are saying

  • Skyrizi growth decelerated from 31.9% to 29.2% YoY, risking investor de-rating of 123x P/E valuation
  • U.S. House probe into China trials alleging PLA ties could trigger sanctions and force abandonment of China trial pipeline
  • Emraclidine Phase II schizophrenia trial failure knocked stock 12% and expects $1.3B IPR&D charge trimming EPS by 71¢

What makes AbbVie unique

  • Skyrizi and Rinvoq form a leading IL-23 and JAK immunology franchise offsetting Humira's 39% decline
  • Maviret is the only EU-approved treatment for both acute and chronic hepatitis C virus infection
  • Boey is Health Canada's first rapid-onset serotype E botulinum neurotoxin for glabellar lines

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
WirtschaftsWoche
Jun 19th, 2026
AbbVie reportedly set to acquire Apogee Therapeutics after $1.3B Blackstone funding

AbbVie is reportedly nearing an acquisition of Apogee Therapeutics, a biotechnology company developing therapies for inflammatory and immune diseases. Founded in 2022, Apogee recently secured financing of up to $1.3 billion from Blackstone Life Sciences last month to fund late-stage development and potential commercialisation of an eczema medication. No further details about the potential deal's terms or valuation have been disclosed.

National Institute for Labor Relations Research
Jun 11th, 2026
AbbVie adds new location in Right to Work North Carolina.

AbbVie adds new location in Right to Work North Carolina. AbbVie is planning to establish operations in Right to Work Durham, North Carolina. The $1.4 billion investment is expected to create 734 new jobs for the community. Exciting! From Area Development Magazine: "Our investment in North Carolina represents a significant milestone for AbbVie as our largest capital investment to date and an important expansion of our manufacturing footprint into a new region of the United States. [...] By establishing this campus, we are strengthening our ability to support future medical breakthroughs while also creating new jobs and a long-term partnership with Durham and the State of North Carolina." [...] "This decision further cements North Carolina's position at the forefront of the global life sciences industry. [...] As our pharmaceutical sector grows, we remain fully committed to cultivating the highly skilled workforce, infrastructure, and ecosystem needed to deliver lifesaving medicines to patients around the world for companies like AbbVie." [...] "We are thrilled to welcome this significant investment, which serves as a powerful testament to Durham's growing reputation as a premier global hub for innovation and talent. [...] Beyond the economic impact, this partnership highlights the company's deep-rooted commitment to our community through sustainable growth and meaningful local engagement. Their decision to call Durham home reinforces our shared vision of a thriving, inclusive economy where corporate success and community prosperity go hand in hand." [...] "With continuous reinvestment in its training infrastructure, North Carolina remains eager to expand upon its strengths in biomanufacturing. [...] We are thrilled that AbbVie has selected Durham County and look forward to partnering to support the success of their North Carolina team." [...] "We're incredibly grateful that AbbVie chose Durham, bringing more than 700 high-quality jobs with six-figure average salaries. This is what real economic mobility looks like - creating pathways into the life sciences industry for more of our residents. [...] This win reflects what makes Durham special - strong partnership with the County, the Chamber, and coordinated execution across every City department, and we're proud to welcome AbbVie as a long-term community partner committed to our future." AREA DEVELOPMENT MAGAZINE

AllSci
Apr 13th, 2026
Haisco Pharma hands novel pain compound portfolio to AbbVie for USD 745m.

Haisco Pharma hands novel pain compound portfolio to AbbVie for USD 745m. April 13, 2026 A portfolio of novel pain compounds developed by Haisco Pharmaceutical Group (SZSE: 002653) has been licensed exclusively to AbbVie (NYSE: ABBV) under an agreement announced April 10, 2026. The deal grants AbbVie rights to develop, manufacture, and commercialize the compounds globally, excluding mainland China, Hong Kong, and Macau. The program covers multiple compounds at stages ranging from preclinical to Phase I in China, all targeting pain-related indications. Under the terms, Haisco receives a USD 30 million upfront payment and is eligible for up to USD 715 million in aggregate development, regulatory, and commercial milestones, bringing the total potential deal value to USD 745 million. Haisco is also eligible for tiered royalties on future net sales. Specific milestone triggers and royalty rates were not disclosed. Deal context. The compounds involved are described by Haisco as novel medicines for pain, but the press release does not identify specific molecule names, biological targets, or mechanisms of action. Haisco is known to be pursuing fast-follower NaV1.8 programs - targeting a voltage-gated sodium channel expressed in peripheral sensory neurons that plays a key role in pain signal transmission - following the approval of Vertex Pharmaceuticals' suzetrigine (Journavx) in January 2025. The Chinese firm has secured patents describing VX-548-derived scaffolds incorporating bioisosteric substitutions to modify the core structure. AbbVie has identified neuroscience as a core therapeutic focus alongside its established positions in immunology and oncology. However, the company has had limited recent deal activity specifically in pain, suggesting the Haisco transaction may represent an effort to expand its position in this segment within a broader neuroscience strategy. Other deals of note in the neuroscience space include the USD 8.7 billion acquisition of Cerevel Therapeutics in 2023, focused on later-stage CNS assets for schizophrenia, Parkinson's, and epilepsy. The deal also represents the latest collaboration between AbbVie with China-based partners. In January 2026, AbbVie struck a deal worth in excess of USD 5 billion with Remegen for a PD-1/VEGF bispecific antibody, while two separate partnerships were signed in 2025, with Zelgen Biopharmaceuticals for T-cell engagers, and Simcere Pharma for a trispecific antibody. For Haisco, the deal represents an extension of an international out-licensing strategy the company has pursued since 2015. Other notable partners include US based biotech AirNexis, which signed a deal worth in excess of USD 1 billion in January 2026 for PDE/4 respiratory asset of Haisco, HSK39004 The Chengdu-based company has R&D operations in Shanghai and Silicon Valley and has previously pursued international expansion through out-licensing, co-development, and acquisitions. Previous multinational partners include US biotech AirNexis and Italy's Chiesi Farmaceutici SpA. Your email address will not be published. Required fields are marked *

AInvest
Apr 13th, 2026
Haisco pharmaceuticals enters exclusive licensing agreement with AbbVie for pain medicines development.

Haisco pharmaceuticals enters exclusive licensing agreement with AbbVie for pain medicines development. Monday, Apr 13, 2026 2:26 am ET 1min read Haisco Pharmaceutical Group has entered into an exclusive licensing agreement with AbbVie to develop novel medicines for pain treatment globally, excluding mainland China, Hong Kong, and Macau. The program includes multiple compounds at various development stages. Haisco will receive a $30 million upfront payment and up to $715 million in milestone payments, plus royalties on future net sales. The collaboration is expected to generate sustainable value and long-term returns. Haisco Pharmaceutical Group has entered into an exclusive licensing agreement with AbbVie to develop and commercialize two Nav1.8 inhibitors for pain treatment outside of mainland China, Hong Kong, and Macau. The compounds, HSK55718 and HSK51155, are intended for the development of non-opioid analgesics and are at different stages of clinical development. HSK55718 is in Phase I clinical trials in China as an intravenous therapy, while HSK51155 is in the preclinical stage as an oral formulation according to the announcement. Under the terms of the agreement, Haisco will receive a $30 million upfront payment and is eligible for up to $715 million in milestone payments, in addition to royalties on future net sales. AbbVie will also cover certain research and development costs through the proof-of-concept phase. The deal is expected to support Haisco's global expansion and enhance its long-term profitability. The collaboration aligns with Haisco's strategy to advance its innovative drug portfolio and strengthen its international commercialization efforts. Ask Aime: What are the potential impacts of Haisco's licensing deal with AbbVie on its stock performance? Aime insights. What's the performance trend of major Indian companies listed on US stock exchanges? Between Microsoft and Google, which is better for long-term holding? How to evaluate a company's competitive advantage? How does R&D spending compare among semiconductor leaders over years?

WN.com
Apr 12th, 2026
AbbVie showcases late-breaking phase 2 data for mirvetuximab soravtansine-gynx (ELAHERE(R) in platinum-sensitive ovarian cancer (PSOC) at SGO 2026.

AbbVie showcases late-breaking phase 2 data for mirvetuximab soravtansine-gynx (ELAHERE(R) in platinum-sensitive ovarian cancer (PSOC) at SGO 2026.